1	A Habenula Neural Biomarker Simultaneously
2	Tracks Weekly and Daily Symptom Variations
3	during Deep Brain Stimulation Therapy for
4	Depression
5 6 7	Shi Liu ^{1,2,3,7} , Yu Qi ^{1,3} , Shaohua Hu ⁴ , Ning Wei ⁴ , Jianmin Zhang ⁵ , Junming Zhu ⁵ , Hemmings Wu ⁵ , Hailan Hu ⁶ , Yuxiao Yang ^{1,2,3,5*} and Yueming Wang ^{1,3*}
8 9	¹ MOE Frontier Science Center for Brain Science and Brain-machine Integration, Nanhu Brain-computer Interface Institute, Hangzhou, 310058, China.
10	² State Key Laboratory of Brain-machine Intelligence, Hangzhou, 311100, China.
11	³ College of Computer Science and Technology, Zhejiang University,
12	Hangzhou, 310058, China.
13 14	⁴ Department of Psychiatry, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
15 16	⁵ Department of Neurosurgery, The Second Affiliated Hospital of Zhejiang University, Hangzhou, 310058, China.
17	⁶ School of Brain Science and Brain Medicine, Zhejiang University,
18	Hangzhou, 310058, China.
19	⁷ Lingang Laboratory, Shanghai, 200031, China.
20 21	* Corresponding author(s). E-mail(s): yuxiao.yang@zju.edu.cn; ymingwang@zju.edu.cn
22	
23	Running title: A Habenula Biomarker for Depression DBS Therapy
24	Keywords: deep brain stimulation; treatment-resistant depression; habenula; local
25	field potential; neural biomarker; machine learning

Abstract

27 Deep brain stimulation (DBS) targeting the lateral habenula (LHb) is a promising 28 therapy for treatment-resistant depression (TRD) but its clinical effect has been 29 variable, which can be improved by adaptive DBS (aDBS) guided by a neural 30 biomarker of depression symptoms. A clinically-viable neural biomarker is desired to 31 classify depression symptom states, track both slow and fast symptom variations 32 during the treatment, respond to DBS parameter alterations, and be neurobiologically 33 interpretable, which is currently lacking. Here, we conducted a study on one TRD 34 patient who achieved remission following a 41-week LHb DBS treatment, during which we assessed slow symptom variations using weekly clinical ratings and fast 35 36 variations using daily self-reports. We recorded daily LHb local field potentials (LFP) 37 concurrently with the reports during the entire treatment process. We then used 38 machine learning methods to identify a personalized depression neural biomarker 39 from spectral and temporal LFP features. The identified neural biomarker classified 40 high and low depression symptom severity states with a cross-validated accuracy of 41 0.97, with the most contributing spectral and temporal feature being LFP beta band 42 power and Hurst exponent, respectively. It further simultaneously tracked both 43 weekly (slow) and daily (fast) depression symptom variation dynamics, achieving test 44 data explained variance of 0.74 and 0.63, respectively. It also responded to DBS 45 frequency alterations. Finally, it can be neurobiologically interpreted as indicating 46 changes in LHb excitatory and inhibitory balance during DBS treatment. Together, our results hold promise to identify clinically-viable neural biomarkers to facilitate 47 future aDBS for treating TRD. 48

49 **1. Introduction**

50 Major depressive disorder (MDD) is one of the most common neuropsychiatric 51 disorders, affecting over 300 million individuals worldwide [1]. Approximately 30% 52 of MDD patients are treatment-resistant, meaning they do not respond adequately to 53 at least two antidepressant trials [2]. Deep brain stimulation (DBS) is a neurosurgical procedure that allows targeted circuit-based neuromodulation [3]. It has emerged as a 54 55 promising treatment option for patients with treatment-resistant depression (TRD) [4-56 6], as shown by open-label studies targeting various brain structures involved in the 57 brain's "reward" system that mediates positive motivations. Such targets include the subcallosal cingulate cortex (SCC) [7], the ventral capsule/ventral striatum (VC/VS) 58 [8], the medial forebrain bundle (MFB) [9], and the bed nucleus of the stria terminalis 59 60 (BNST) [10]. However, several recent double-blinded clinical trials have shown that 61 the effects of DBS targeting these brain structures are inconsistent across patients 62 [11-15]. As a potential improvement over DBS, adaptive DBS (aDBS) optimizes DBS parameters in real-time by using neural signals as feedback for enhancing 63 64 clinical efficacy [16]. A recent study implements aDBS targeting VC/VS in a TRD 65 patient by triggering stimulation only when the local field potential (LFP) signal 66 pattern indicates worsening of depression symptoms, achieving rapid alleviation of 67 depression symptoms [17].

68 The lateral habenula (LHb) is a hub structure that plays a central role in the brain's 69 "anti-reward" system that mediates negative motivations [18–20]. Animal studies 70 have systematically shown that the local bursting firing patterns in LHb are closely 71 related to depression-like behaviors and that neuromodulation of LHb has significant antidepressant effects [21–23]. Several clinical studies have reported single-patient depression symptom alleviation following LHb DBS since 2010 [24–27]. On the other hand, two recent clinical studies on seven or six patients has shown more variable effects of LHb DBS across patients [28,29]. Similar to other DBS targets, aDBS for LHb also provides a promising path towards improved and more consistent treatment effects across TRD patients.

78 A critical and fundamental requirement for developing LHb aDBS is the identification of an LHb neural biomarker of depression symptoms during the DBS 79 80 treatment to provide the necessary feedback signal [30,31]. A population-level SCC 81 LFP spectral power biomarker has been identified for tracking depression symptom 82 recovery with SCC DBS in five TRD patients [32]. Personalized amygdala and BNST LFP gamma power biomarkers have been identified for optimizing VC/VS DBS [33]. 83 84 For LHb DBS, LFP signals have been recorded before the DBS treatment starts but 85 not during the multi-month-long treatment process [28,29,34] and several studies 86 have found statistical correlations between pre-treatment LHb LFP spectral features 87 and after-treatment depression symptom ratings [28,29,34]. However, it is unknown 88 whether the identified LFP features can classify depression symptom severity states 89 or track the temporal dynamics of depression symptom variations during the DBS 90 treatment process. Therefore, a useful neural biomarker for realizing LHb aDBS is still lacking. 91

A clinically-viable neural biomarker is desired to be able to track both the slow and fast temporal dynamics of depression symptom variations during DBS. This is because both natural and DBS-induced depression symptom changes can vary at different time scales, with both slow-changing dynamics over months or weeks [35–

96 39] and fast-changing dynamics over hours or days [9,40-43]. Existing neural 97 biomarker studies have focused on tracking the temporal dynamics of either slow or 98 fast symptom variations. The aforementioned SCC neural biomarker for SCC DBS 99 tracks the temporal dynamics of the weekly symptom variations over 24 weeks [32]. 100 The aforementioned amygdala and BNST neural biomarkers for VC/VS DBS track 101 the faster temporal dynamics of symptom variations within several days [17,33]. 102 Several other studies have also identified resting-state (without DBS) neural 103 biomarkers of relatively fast depression symptom variations within several days using 104 multisite intracranial electroencephalography (iEEG) [44-46]. However, to date, 105 identifying a neural biomarker that can simultaneously track the temporal dynamics 106 of both slow and fast depression symptom variations, in particular during LHb DBS 107 treatment, remains elusive.

108 Moreover, the neural biomarker needs to reflect the dose effect of different DBS 109 parameters for optimizing stimulation parameters in aDBS. Since the DBS 110 mechanism for treating TRD is largely unknown [47], only few studies have experimentally explored the dose effect of different DBS amplitudes on human neural 111 112 signals [17,32,33]. On the other hand, DBS frequency also has been shown to play a 113 key role in altering TRD symptoms [4-6,48]. However, how different LHb DBS parameters, especially stimulation frequencies, alter neural signals or neural 114 115 biomarkers in TRD patients remains unknown.

Finally, the neural biomarker should possess a certain level of neurobiological interpretability. A critical neurobiological property that has been implicated in the pathophysiology of MDD [21–23] is the excitatory/inhibitory (E/I) balance of LHb activity. E/I balance refers to the equilibrium between synaptic excitation and

120 inhibition received by neurons [49]. LHb has excitatory and inhibitory connections with a wide range of brain regions involved in the affect, reward, and cognition 121 122 dimensions of MDD symptom, such as the dorsal raphe nucleus, nucleus accumbens, hippocampus, medial prefrontal cortex, etc [50]. Excessive excitation of LHb has 123 124 been implicated in the pathology of MDD [21–23]. By contrast, electrical stimulation 125 of LHb in animal depression models has been shown to inhibit overly-excited local 126 neural activity, thus modulating the dopaminergic and serotoninergic activity and 127 generate complex excitatory and inhibitory effects over a large network that may have led to depression-like behavior alleviation [51,52]. Furthermore, a prior study has 128 129 found a correlation between pre-treatment LHb E/I balance with depression 130 symptoms in DBS patients [34]. However, how LHb E/I balance changes during 131 human patient DBS treatment and whether there exists a neural biomarker that can 132 track such changes has not been investigated.

133 Here, to close the above gaps, we conducted LHb DBS on one TRD patient where 134 we evaluated the patient's symptoms and concurrently collected daily LHb LFP 135 signals during the entire 41-week long treatment process (Figure 1). With this unique 136 longitudinal dataset and by using machine learning techniques, we identified a 137 clinically-viable neural biomarker from spectral and temporal LHb features, where the most contributing spectral and temporal features are the β (12-30 Hz) band power 138 and Hurst exponent, respectively. Our identified neural biomarker (1) accurately 139 140 classified high and low depression symptom severity states; (2) significantly tracked 141 the temporal dynamics of weekly (slower) and daily (faster) depression symptom variations during the DBS treatment; (3) reflected the depression symptom changes 142



Figure 1. Study framework. During the LHb DBS treatment of one TRD patient, we used weekly clinical ratings and daily self-reports to evaluate the symptom variations, where we simultaneously collected daily LFP signals from LHb. Using machine learning models, we identified a neural biomarker that classified high and low depression symptom states during the DBS treatment. Using data not used in neural biomarker identification, we evaluated and interpreted the neural biomarker in terms of 1) simultaneously tracking the temporal dynamics of weekly slow and daily fast variations of depression symptoms; 2) reflecting symptom changes when DBS frequencies were altered; 3) indicating changes in LHb E/I balance.

in response to DBS frequency alterations. Finally, the neural biomarker can be
interpreted as an indicator of the changes in LHb E/I balance during the DBS
treatment. Together, our results have implications for identifying clinically-viable
neural biomarkers to facilitate future LHb aDBS developments for treating TRD.

147 2. Materials and Methods

148 2.1 Participant

This study included a male TRD patient aged 36-40 years old (see Note S1 for detailed
patient medical information) participating in a clinical trial of LHb DBS treatment
starting in October 2021. The patient provided informed consent for participation in

the clinical trial. This study received approval from the Ethics Committee of Zhejiang University School of Medicine Second Affiliated Hospital (protocol number 20210218). It was registered at www.clinicaltrials.gov (IR2021001074), where detailed information regarding the inclusion and exclusion criteria can be accessed.

156 At the beginning of the clinical trial, two independent psychiatrists evaluated the patient's psychotic symptoms using the 17-item Hamilton Depression Rating Scale 157 (HAMD), the Montgomery Asberg Depression Scale (MADRS), and the Hamilton 158 159 Anxiety Rating Scale (HAMA) as baseline assessments. In addition to the psychiatric 160 assessments, the patient underwent a comprehensive physical examination, various 161 mental scale assessments, and a magnetic resonance imaging (MRI) examination. We carefully ensured that other psychiatric diagnoses outlined in the Diagnostic and 162 Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) were excluded. 163

164

2.2 Surgical procedure

165 A standard DBS implantation procedure was employed. Bilateral quadripolar electrodes (1200-40, SceneRay, Suzhou, China) were surgically implanted in the LHb 166 167 under local anesthesia (Figure 2A). The DBS electrodes had a diameter of 1.27 mm and a lead length of 400 mm. Each electrode's four contacts measured 1.5 mm in 168 length with a spacing of 0.5 mm. The LHb targeting was guided by preoperative MRI 169 sequences. After confirming the absence of stimulation side effects through 170 171 intraoperative testing, an implantable pulse generator (SR1101, SceneRay) was 172 placed under general anesthesia. The DBS device was also capable of recording and 173 wireless transmitting LFP signals (Figure 2B).



Figure 2. Experiment design. (A) MRI visualization showing the DBS lead placement within the patient's LHb. The shaded blue area indicates the volume of tissue activated by the DBS. (B) Temporal dynamics of example epochs of LFP signals after preprocessing. (C) LHb DBS Treatment Timeline. The entire treatment process consisted of six stages. LFP signal collection began after the activation of 1 Hz stimulation. (D) Longitudinal data collection over time. Data were collected using two different time scales: 1) daily self-reports and 30-min LFP signals recorded around the self-reports; 2) weekly clinical ratings.

174 2.3 Fiber tracking of LHb

We used diffusion tensor images from the magnetic resonance imaging (MRI) examination to conduct fiber tracking of LHb with a standard procedure reported in a previous study [53]. First, we manually created the LHb as the region of interest (ROI) in standard Montreal Neurological Institute 152 (MNI152) space. The ROI in MNI152 standard space was then registered to the diffusion space of our patient for

180 tractography. To ensure the exclusion of non-brain tissue, we employed the 'bet2' 181 function, and the cerebrospinal fluid mask was used as an exclusion mask. We further 182 performed the probabilistic tractography processing using tools from the FSL 183 Diffusion Toolbox. The LHb ROI was used as the seed mask to generate whole-brain distribution maps using FSL's probtrackX tool. We performed 5000 streamline 184 185 samples per voxel with distance normalization to ensure comprehensive coverage. 186 Subsequently, the resulting fiber distribution maps were non-linearly registered back to the MNI152 standard space. To eliminate artifactual connections and noise, a 187 threshold value of 1% was implemented. 188

189 **2.4 DBS treatment process and symptom evaluations**

190 During the bilateral DBS treatment process, we made multiple adjustments to the stimulation parameters to achieve the best therapeutic effect. We divided the treatment 191 192 process into six stages based on the alterations of stimulation parameters (Figure 2C): 1) the "Preop" stage, the time before DBS implantation; 2) the "Off-1" stage, patient 193 194 recovery with DBS turned off; 3) the "1 Hz" stage, activation of 1 Hz stimulation; 4) 195 the "Off-2" stage, DBS turned off because of unnoticed power off; 5) the "20 Hz" 196 stage, re-activation of 20 Hz stimulation; 6) the "130 Hz" stage, activation of 130 Hz stimulation. More details can be found in Note S2. The entire duration of DBS 197 198 treatment spanned 41 weeks (starting from DBS implantation).

The efficacy of DBS treatment was evaluated from two perspectives: clinician evaluation and self evaluation (Figure 2D). For clinician evaluation, a psychologist blinded to the current stimulation parameters and their adjustments evaluated the patient's depression and anxiety symptoms on a weekly basis using standardized 203 rating scales (HAMD, MADRS, HAMA). Response is defined as a 50% or greater improvement on the HAMD score from the pre-treatment baseline. Remission is 204 205 defined as achieving a HAMD score of 7 or less. The psychologist also evaluated the patient's emotional blunting and cognitive functioning during the treatment. For every 206 207 four to six months, the psychologist utilized the Oxford Depression Questionnaire 208 (ODQ), a self-report tool to assess emotional blunting, along with two cognitive 209 assessment tools (MATRICS Consensus Cognitive Battery (MCCB) and THINC-210 integrated tool (THINC-it)) to evaluate the patient's cognitive abilities. For self 211 evaluation, the patient used the Visual Analogue Scale (VAS) for depression (VAS-D) 212 and anxiety (VAS-A) to self-report the symptom severity. Self-reported VASA and 213 VAS-D had been used to assess the rapid effects of antidepressants [54]. To facilitate 214 daily data collection, we established an online questionnaire system where the patient 215 could conveniently complete the self-reports via the smartphone or computer.

216 **2.5** LFP signal recording, signal processing, and feature

217 **extraction**

After activating the 1 Hz stimulation, we collected daily LFP signals (30 minutes per 218 219 day) concurrent with daily self-reported VAS-D and VAS-A (Figure 2D, details in 220 section 2.4). LFP signals were recorded at a sampling rate of 1000 Hz. Notably, 221 stimulation was deactivated during the signal acquisition process. We reconstructed 222 the electrode positions using MRI and selected two contacts in the left hemisphere for 223 bipolar recording of a single LFP channel. The patient was instructed to attempt daily 224 LFP recording and VAS-D/VAS-A reporting. Throughout the entire 41-week (287-225 day) treatment, the patient was able to activate LFP recording and report VAS-D and VAS-A on 122 days distributed across 26 weeks. Therefore, the subsequent analyses

227 focused on the LFP signals, VAS-D, and VAS-A scores recorded from these 122 days,

and the HAMD, MADRS, and HAMA scores recorded for the 26 weeks.

Custom MATLAB scripts (MathWorks Inc., Natick, MA, USA) were used to preprocess the LFP signals. The LFP signals were first band-pass filtered from 1 to 30 Hz using a Butterworth filter of order 12 to avoid the noise observed in higher frequency bands. Then, we divided the daily 30-minute LFP signals into 10-second epochs with a 50% overlap. Next, we used a standard procedure (details in Note S4) to remove bad epochs from daily LFP signals (example temporal traces of preprocessed LFP epochs were shown in Figure 2B).

236 For each remaining LFP epoch, we computed its spectral domain (SD) and 237 temporal domain (TD) features. SD features included PSD of the four bands (δ (delta, 238 1-4 Hz), θ (theta, 4-8 Hz), α (alpha, 8-12 Hz), and β (beta, 12-30 Hz)) and phaseamplitude coupling (PAC) for six specific pairs of coupling. TD features included 239 240 fourteen temporal domain features used in previous study [55], e.g., Hjorth mobility, 241 Higuchi fractal dimension, Kurtosis, peak-to-peak amplitude, Hurst exponent, etc. 242 These features capture the temporal properties of LFP from probabilistic distribution and information theory perspectives and have been widely used in brain signal 243 analyses [56,57]. As a result, we obtained 24 features, comprising 10 SD features and 244 245 14 TD features for each LFP epoch. Details of these 24 features are included in Table 246 S1 and Note S3. Finally, we averaged each feature across LFP epochs within the same 247 day and obtained a single averaged 24-dimensional LFP feature vector. Our subsequent analyses were based on the daily LFP features as computed above. 248

249 2.6 Correlational analyses between LFP features and symptoms

We conducted Spearman's rank correlation analyses between LFP features and symptoms. For each day, we correlated each daily LFP feature with the daily VAS-D and VAS-A. For each week, we computed the average of LFP features across the days that belonged to this week, resulting in weekly LFP features; we then correlated each weekly LFP feature with the weekly clinical evaluation scales HAMD, HAMA, and MADRS. Bonferroni correction was used to adjust for multiple comparisons.

256 2.7 Identification of neural biomarker

Next, we used a data-driven method to identify an LHb neural biomarker of
depression symptoms, where we built a machine learning model to use LFP features
to classify high and low depression symptom states.

First, we defined the high and low depression symptom states of the patient by kmeans clustering the weekly depression scales HAMD and MADRS similar to prior work [17]. Among the total 26 weeks (122 days) of LFP data, 7 weeks (29 days) of LFP data belonged to the low depression symptom state (labeled 0), 4 weeks (22 days) of LFP data belonged to the high depression symptom state (labeled 1). The remaining 15 weeks (71 days) belonging to the transition symptom state were unlabeled and used as test data for subsequent biomarker tracking evaluation (see next section).

267 Second, based on the labeled data, we built a machine learning model to use the 268 LFP features to classify high and low depression symptom states. We constructed six 269 machine learning models: logistic regression (LR), multilayer perceptron, adaptive 270 boosting, support vector machine, random forest, and linear discriminant analysis. We trained and tested these models using 5-fold cross-validations that were repeated 200
times, where we computed the averaged cross-validated classification accuracy,
specificity, sensitivity, F1 score, and Receiver Operating Characteristic (ROC) Area
Under the Curve (AUC) score as the performance metrics. The model with the highest
accuracy was selected for further analyses.

Third, the chosen model was retrained with all labeled data, leading to a "neural biomarker model". This model takes the LFP feature as input and outputs the decision variable as the neural biomarker value (e.g., in the LR model, the decision variable was computed from the decision probability via the inverse sigmoid function). This allows us to compute a neural biomarker value for any given LFP feature. Higher neural biomarker values indicate more severe depression symptoms.

In essence, our identified neural biomarker aggregates spectral and temporal domain features from the LHb LFP signal to classify high and low depression states during DBS treatment.

285 **2.8 Evaluation of the neural biomarker**

We evaluated the neural biomarker in terms of (1) tracking the temporal dynamics of
weekly symptom variations; (2) tracking the dynamics of daily symptom variations;
(3) reflecting changes in symptom variations induced by DBS frequency alterations.

First, we investigated tracking the temporal dynamics of weekly depression and anxiety symptom scales that were not used in neural biomarker identification. We took the daily LFP features as inputs to the neural biomarker model and computed the output daily neural biomarkers. We then averaged the daily neural biomarkers belonging to the same week to compute the weekly neural biomarkers. We next 294 correlated the weekly neural biomarker values with the weekly HAMD, MADRS, and HAMA scores, respectively, using Spearman's rank correlation analyses with 295 296 explained variance (EV) as an estimation. We further analyzed the temporal dynamics in the neural biomarker and symptoms, using the dynamic time warping (DTW) 297 298 distance [58] to measure the temporal tracking ability of the neural biomarker. Both 299 the neural biomarker values and the symptom scales were normalized to a range of 0 300 to 1. We used a size three Sakoe-Chiba warping window in the DTW analysis 301 following prior work [17,59]. A smaller DTW distance represents better temporal 302 tracking. To determine the significance of the computed DTW distance, we randomly 303 shuffled the temporal sequence of the neural biomarker 10,000 times and used the 304 corresponding shuffled DTW distances as the null hypothesis distribution for 305 computing the *P* value.

306 Second, we investigated tracking the temporal dynamics of the daily VAS-D and 307 VAS-A self-reports, which were also not used in neural biomarker identification. 308 Similar to the weekly case, daily LFP features were used to generate daily neural 309 biomarkers, which were then correlated with daily VAS-D and VAS-A reports. DTW 310 was again used to assess the temporal tracking of daily depression symptom variations. 311 Third, we qualitatively compared trends in weekly neural biomarkers and 312 depression ratings across three DBS frequency alterations (1 Hz to Off-2, Off-2 to 20 313 Hz, 20 Hz to 130 Hz). We used the two-sided Wilcoxon rank-sum test to check whether 314 there was a significant difference between the two stages before and after alteration. We also averaged the neural biomarker values and depression ratings across five time 315 periods for each case: 1) from the beginning of this stage to two weeks before the 316 317 alteration week; 2) during the week before the alteration week; 3) during the alteration

week; 4) during one week after the alteration week; 5) averaged from two weeks afterthe alteration week to the end of this stage.

320 **2.9** Interpretation of the neural biomarker

321 We then conducted multiple analyses to interpret the neurobiological implications 322 of the identified neural biomarker. First, we recognized the most contributing spectral 323 and temporal LFP features of the neural biomarker. To evaluate their contributions, 324 we performed individual classification of the high and low symptom states using each 325 feature separately. The performance of the classification provided an indication of the 326 level of information contained within each feature regarding the symptom state. To 327 further validate the contribution of these features, we compared the weights of each 328 feature in the neural biomarker identification model (see Section 2.7).

329 Second, we related the neutral biomarker to the LHb E/I balance. Following prior 330 work [60], we computed the LFP spectrum's 1/f slope as a quantitative indicator of 331 E/I balance, where a larger absolute 1/f slope indicates more inhibition. More specifically, after calculating the PSD of the remaining epochs after the removal of 332 bad epochs (see Section 2.5), we averaged the spectrum across LFP epochs within the 333 334 same day and selected a frequency range of interest to be 1-30 Hz (our signal spectrum range). We then estimated 1/f slope from the log-transformed PSD using linear 335 336 regression, with the coefficient representing the 1/f slope. We next normalized the E/I 337 indicator by computing the percentage change relative to the 1/f slope of the first LFP 338 recording day. We finally correlated this E/I indicator with the identified neural 339 biomarker and its most contributing features using standard Spearman's rank 340 correlation analyses.

341 **3. Results**

342 **3.1** LHb DBS improved the patient's depression symptoms,

343

emotional blunting, and cognitive functions

344 We first examined the TRD patient's depression and anxiety symptom changes 345 throughout the LHb DBS treatment process. At the beginning of treatment, the 346 patient's baseline HAMD score was 20, MADRS score was 25, and HAMA score 347 was 16. In terms of the weekly clinical ratings (Table 1 and Figure 3A), the patient responded at week 14 (HAMD score dropped to 10; MADRS score dropped to 19; 348 349 HAMA score dropped to 8) and achieved remission by the end of the 41-week 350 treatment (HAMD score was 7; MADRS score was 9; HAMA score was 6). The daily 351 self-reports followed a similar decreasing trend (Figure 3B). Such a consistent trend 352 was confirmed by the strong positive correlation between the daily self-reports and weekly clinical ratings (Spearman's $\rho > 0.5$, P < 0.05 for all pair-wise 353 correlations; see Table S2 and Figure S1 for details). 354

Table 1. Assessment of depression and anxiety symptoms with weekly clinical ratings. mean±s.e.m.

Weekly clinical					
ratings	Baseline	1Hz	Off-2	20Hz	130Hz
C	N=1	N=4	N=3	N=15	N=14
HAMD	20	11.00±0.41	12.33±0.88	9.20±0.46	6.86±0.25
MADRS	25	18.75±0.48	21.00±1.00	17.93±0.63	10.64±0.56
HAMA	16	9.75±0.48	11.67±0.33	9.80±0.39	8.29±0.38

357



Figure 3. Changes of weekly and daily symptom scores during the LHb DBS treatment. (A) Changes of weekly clinical ratings during the treatment. The vertical dashed lines represent different treatment stages indicated by the x-axis labels. (B) Changes of daily self-reports during the treatment. The vertical dashed lines represent different treatment stages indicated by the x-axis labels.

Besides alleviating depression and anxiety symptoms as indicated by the weekly 358 clinical ratings and daily self-reports, LHb DBS also improved the patient's emotional 359 360 blunting and cognitive functioning. The total scores of ODQ dropped from the presurgery baseline of 117 to 94, and most of the ODO subdomains continuously 361 362 decreased during the DBS treatment (Table 2), indicating an improvement of emotional blunting. MCCB and THINC-it as cognitive function instruments 363 364 suggested cognitive performance improved compared to the presurgery baseline (Table 3). Specifically, in the MCCB test, persistent improvements were found in 365 366 processing speed, verbal learning, visual learning, reasoning/problem solving, and 367 social cognition, while attention and working memory temporarily improved but 368 fluctuated during the treatment. In the THINC-it test, the performance of Symbol 369 check and Trail task, which were highly related to working memory [61] and

- 370 executive functioning [62], showed persistent improvements, while PHQ-D-5,
- 371 Spotter, and CodeBreaker task performance fluctuated.

Table 2. Assessment of emotional blunting with Oxford Depressive Symptoms Questionnaire (ODQ).

Domains of ODQ	Follow up after activation of stimulation			
	Baseline	69 days	173 days	270 days
General Reduction	23	24	23	19
Reduction in Positive	25	25	24	20
Emotional Detachment	25	25	16	18
Not Caring	22	23	18	18
Antidepressant as Cause	22	22	18	19
Total	117	119	99	94

Table 3. Assessment of cognitive functioning with MATRICS Consensus Cognitive Battery (MCCB) and THINC-it.

	Domains of MCCB		Follow up after activation of stim.		
		Baseline	173 days	271 days	
	Processing Speed	27	55	55	
MATRICS	Attention/Vigilance	24	41	37	
Consensus Cognitive	Working Memory	47	58	52	
Battery	Verbal Learning	36	40	43	
	Visual Learning	52	63	63	
	Reasoning/Problem Solving	30	44	42	
	Social Cognition	25	29	28	
	Domains of THINC-it	Follow up after activation of stin			
		Baseline	69 days	271 days	
	PHQ-D-5	600	400	1000	
THINC-it	Spotter (Reaction time)	2128	2192	656	
	Symbol check (N-back)	1332	2000	2334	
	CodeBreaker (Digit symbol substitution)	850	1150	950	
	Trails (Trail making test)	1103	2096	2191	

376 3.2 Multiple spectral and temporal LHb LFP features

377 significantly correlated with symptom changes

During the LHb DBS treatment process, we recorded daily LHb LFP signals. Therefore, we then investigated how the LFP features correlated with the patient's symptom changes (Figure 4A). We found that many of the temporal and spectral domain LHb LFP features were significantly correlated with the weekly clinical



Figure 4. Correlations between the symptom evaluations (weekly and daily symptom scores) and the LFP features (temporal and spectral domain features). (A) Schematic diagram of correlation analysis. (B) Heatmap of the correlation coefficients. Each cell shows the correlation coefficient (CC) value between one LFP feature (y-axis) and one symptom score (x-axis), and cells marked with * indicate the coefficients that are significantly different from zero (Bonferroni corrected p < 0.05). (C) Positive and negative correlation examples with the weekly HAMD score and daily VAS-D score as shown by the yellow boxes in (B).

ratings and daily self-reports (Figure 4B). For example, Hurst exponent exhibited the
strongest correlations with both weekly HAMD scores and daily VAS-D scores
(Figure 4C). The results indicate that it is feasible to identify an LHb neural biomarker
of depression symptoms from the LFP temporal and spectral domain features.

386

3.3

Accurate classification of high and low symptom severity

387

states led to the identification of an LHb neural biomarker

388 We next used the LFP temporal and spectral features to identify a neural biomarker 389 that can classify high and low depression symptom severity states (Figure 5A). We started by defining a state of high symptom severity and a state of low symptom 390 391 severity via clustering the weekly depression scales HAMD and MADRS (Figure 5B). 392 The high symptom state (7 weeks) had an average HAMD score of 12.8 and an 393 average MADRS score of 22.5, while the low symptom state (4 weeks) had an 394 average HAMD score of 6.3 and an average MADRS score of 9.0. We then used LFP 395 temporal domain and spectral domain features from these 11 weeks to classify the high and low symptom severity states via six machine learning models in cross-396 397 validation. Among these six models, the LR model performed better than other more 398 complicated models (Figure 5C and table S3). Specifically, for the LR model, the 399 cross-validated classification accuracy was 0.973 ± 0.002 (mean \pm s.e.m.), the 400 specificity was 0.961±0.003, the sensitivity was 0.988±0.002, the F1-score was 0.970±0.002, and the AUC score was 0.974±0.001, which were all significantly 401 402 higher than other models (Wilcoxon rank sum test, Bonferroni corrected P < 0.05 for 403 all comparisons), suggesting that the LR model was best suited for classifying the 404 collected data. We thus selected the LR model for further analyses. Then, we retrained



Figure 5. Accurate classification of high and low depression symptom severity states by the identified neural biomarker. (A) Schematic diagram of neural biomarker identification. Note that the identification was conducted using supervised learning and cross-validation purely based on the weekly data in the high and low symptom states. The rest weekly data in the transition symptom state were used later to test the tracking performance of the identified neural biomarker. (B) Clustering of depression symptom severity states. We clustered the HAMD and MADRS scores to obtain three distinct symptom states: a high depression symptom severity state (shaded in red), a low depression symptom severity state (shaded in blue), and a transition state (shaded in grey). Each point represents data of a week. The average HAMD and MADRS scores of the high and low clusters are also indicated in the figure. (C) Classification performance of different classifiers. The bar represents mean and the whiskers represent the 95% confidence interval. Six classification models (different colors) were compared in terms of five performance matrices (different x-axis groups): accuracy, specificity, sensitivity, F1-Score and AUC. The best model was indicated by a yellow star for each metric. Classification model abbreviations: logistic regression (LR), multilayer perceptron (MLP), adaptive boosting (AdaBoost), support vector machine (SVM), random forest (RF), and linear discriminant analysis (LDA).

- the LR model using the 11 weeks' labeled data, resulting in the neural biomarker
- 406 model, which model took the LFP features as input and output the model decision
- 407 value as the neural biomarker, with higher values indicating worse symptoms.

408

3.4 The identified neural biomarker simultaneously tracked the temporal dynamics of weekly and daily depression symptom 409 variations during LHb DBS treatment 410

411 After identifying the neural biomarker of depression symptoms, we evaluated its 412 ability to track the temporal dynamics of slow (weekly) and fast (daily) depression symptom variations during the LHb DBS treatment. For slow weekly variations, we 413 414 used the identified neural biomarker model to compute weekly neural biomarker 415 values (see Section 2.8). We used the weekly neural biomarker values to predict the 416 associated weekly clinical ratings, where we strictly excluded the weekly data that 417 were used to identify the neural biomarker (i.e., the prediction was based on unseen transition symptom state data not used in training the neural biomarker model, Figure 418 419 6A). We found that the weekly neural biomarker values significantly predicted the HAMD scores (Figure 6B, EV=0.74, $P = 1.1 \times 10^{-5}$). Further, considering the 420 421 temporal dynamics in detail by using the DTW distance analysis (see Section 2.8), we found that the weekly neural biomarker significantly tracked the temporal 422 dynamics of weekly HAMD score variations (random shuffle P = 0.00001). 423 424 Consistently, the weekly neural biomarker values significantly predicted the MADRS scores (Figure 6C, EV=0.34, P = 0.039), and tracked the temporal dynamics in the 425 DTW distance analysis with marginally significant statistics (random shuffle P =426 0.1079). Conversely, the weekly neural biomarker values did not predict the HAMA 427 scores (Figure 6D, EV=0.03, $P = 5.2 \times 10^{-1}$) or tracked the temporal dynamics 428 429 (random shuffle P = 0.5865).

430



Figure 6. Accurate tracking of the temporal dynamics of weekly depression symptom variations by the identified neural biomarker. (A) Schematic diagram of analyzing the neural biomarker's weekly tracking performance. The neural biomarker, derived from the training data of weekly high and low symptom states, was tested by tracking the unseen weekly clinical ratings of transition symptom state. (B) Left: correlation between the identified neural biomarker values and the weekly HAMD scores. CC: correlation coefficient. EV: Explained variance. Middle: neural biomarker tracking of the weekly HAMD score dynamics over time. Right: the DTW distance analysis result for evaluating the significance of tracking in the middle panel. Smaller DTW distance represents better tracking. Note that we normalized both the neural biomarker values and the symptom scales to a range of 0 to 1 using min-max normalization for better visualization. (C) same as (B) but for the weekly MADRS scores.

431	For fast daily variations, we used the identified neural biomarker model to
432	compute daily neural biomarker values and used the daily neural biomarker values to
433	predict the associated daily self-reports (again, data not used in training the neural
434	biomarker model, Figure 7A). We found that the daily neural biomarker values



Figure 7. Accurate tracking of the temporal dynamics of daily depression symptom variations by the identified neural biomarker. (A) Schematic diagram of analyzing the neural biomarker's daily tracking performance. The neural biomarker, derived from the training data of weekly high and low symptom states, was tested by tracking the unseen daily self-reports. (B) Left: correlation between the identified neural biomarker values and the daily VAS-D scores unseen in neural biomarker identification. EV: Explained variance. Middle: neural biomarker tracking of the daily VAS-D score dynamics over time. Right: the DTW distance analysis result for evaluating the significance of tracking in the middle panel. Smaller DTW distance represents better tracking. (C) same as (B) but for the daily VAS-A scores.

- significantly predicted the VAS-D scores (Figure 7B, EV=0.63, $P = 1.3 \times 10^{-27}$)
- 436 and showed significant tracking of VAS-D dynamics (random shuffle P = 0.0001).
- 437 By contrast, while the daily neural biomarker values predicted the VAS-A scores
- 438 (Figure 7C, EV=0.51, $P = 5.3 \times 10^{-16}$) but the daily neural biomarker did not
- 439 significantly track VAS-A dynamics (random shuffle P = 1.00).

440

In summary, the results show that the identified neural biomarker significantly tracked the temporal dynamics of both weekly and daily variations in depression symptoms during the LHb DBS treatment and specifically tracked depression symptoms rather than anxiety symptoms.

445 **3.5** The identified neural biomarker reflected changes of

446

depression symptoms in response to DBS parameter

447 alterations

A useful neural biomarker for DBS also needs to reflect the effect of different DBS 448 449 parameters. We thus evaluated if the identified neural biomarker could reflect changes 450 in depression symptoms in response to DBS parameter alterations. We applied three 451 different DBS frequencies during the treatment: 1 Hz, 20 Hz, and 130 Hz. For the 452 DBS alteration from 1 Hz to stimulation off (Off-2, the DBS device shut down due to 453 unnoticed power off), there was a trend of increasing for the neural biomarker, HAMD, 454 and MADRS while the statistical tests were not significant due to the limited sample 455 size (Figure 8A, 1Hz vs. stimulation off, normalized mean±s.e.m., neural biomarker: 0.912±0.055 vs. 0.956±0.026, P=0.35; HAMD: 0.562±0.062 vs. 0.688±0.036, 456 P=0.16; MADRS: 0.656 ± 0.031 vs. 0.734 ± 0.053 , P=0.35), which indicated a 457 458 rebound trend of depression symptoms due to the disruption of DBS treatment. For the DBS alteration from stimulation off (Off-2) to 20 Hz stimulation, the neural 459 460 biomarker, HAMD, and MADRS consistently decreased (Figure 8B, stimulation off vs. 20 Hz, neural biomarker: 0.905 ± 0.095 vs. 0.545 ± 0.059 , *P*=0.04; HAMD: 461 462 0.875±0.125 vs. 0.375±0.072, P=0.05; MADRS: 0.875±0.000 vs. 0.606±0.061, P=0.08). Specifically, the neural biomarker, HAMD and MADRS scores all 463



Figure 8. The consistent trend between the neural biomarker and the depression symptom changes when DBS frequencies were altered. (A) DBS frequency was altered from 1 Hz to Off-2. Top: comparison of the values of the biomarker, HAMD scores and MADRS scores between the 1Hz stage and Off-2 stage. Two-sided Wilcoxon rank-sum test was used for significance test. Asterisks indicate the significance *p<0.05 and ns indicates no significance. Row two: changes in the identified neural biomarker time-locked to the DBS frequency alteration week (vertical dashed line). Row three: changes in HAMD time-locked to the DBS frequency alteration week. (B) same as (A) but for DBS frequency alteration from Off-2 to 20 Hz. (C) same as (A) but for DBS frequency alteration from 20 Hz to 130 Hz.

464 decreased at the week of DBS frequency alteration, further decreased one week after 465 the alteration and continued to decrease with more obvious changes after week two. 466 For the DBS alteration from 20 Hz to 130 Hz stimulation, the neural biomarker, HAMD, and MADRS also consistently decreased (Figure 8C, 20 Hz vs. 130 Hz, 467 neural biomarker: 0.524±0.060 vs. 0.088±0.029, P=0.001; HAMD: 0.323±0.054 vs. 468 0.042 ± 0.026 , P=0.004; MADRS: 0.573 ± 0.056 vs. 0.062 ± 0.016 , P=0.001). More 469 470 specifically, the neural biomarker, HAMD and MADRS scores already showed a 471 trend of decreasing before the DBS frequency alteration, and the alleviated symptoms 472 stayed relatively stable during the alteration week, at week one after the alteration, 473 and the same stable trend continued after week two. The results suggested that the 1 474 Hz DBS did not induce an obvious change in depression symptoms, while the 20 Hz 475 and 130 Hz DBS had more meaningful effects. The results further showed that the 476 neural biomarker indeed reflected the different change patterns in depression 477 symptoms when the DBS frequencies were altered.

478

3.6 Neural biomarker identification and testing was robust to

479

adequate decreasing of data sample size

480 The neural biomarker was identified and tested by a dataset consisting of 122 days of data samples. Due to the difficulty of obtaining a large amount of longitudinal data, 481 482 we investigated the robustness of neural biomarker identification and testing in terms of data sample size decreasing. We decreased the data sample size gradually from 122 483 to 10 with a step size of 2, randomly removed data from neural biomarker 484 identification and testing for each data sample size, and then repeated the entire neural 485 486 biomarker classification and tracking analyses. We found that the neural biomarker classification accuracy consistently maintained above 0.95 even by decreasing the 487 488 sample size to 70 but had a large decrease below a sample size of 40 (Figure 9A). 489 Similarly, the neural biomarker tracking performance (EV in prediction) maintained 490 relatively stable by decreasing the sample size to 70 but had much larger fluctuations below a sample size of 40 (Figure 9B). These results suggest that our data sample size 491 492 of 122 days was sufficient to obtain a robust neural biomarker.



Figure 9. Changes of the neural biomarker identification and tracking performance by gradually decreasing the data sample size. (A) The accuracy of classifying the high and low symptom states. (B) The tracking performance of depression symptoms (weekly HAMD, weekly MADRS, and daily VAS-D).

3.7 The identified neural biomarker was mainly contributed by the β band spectral feature and the Hurst exponent temporal

495 feature

Having demonstrated the usefulness and robustness of the identified neural biomarker, 496 497 we next aimed to provide neurobiological interpretations for the neural biomarker 498 from multiple aspects. We started by investigating the most contributing spectral and 499 temporal LFP features in the neural biomarker. We recognized the most contributing 500 spectral and temporal LFP features by separately classifying the high and low weekly 501 symptom states using each individual spectral and temporal LFP feature (Figure 10A). 502 The best temporal domain feature was the Hurst exponent, with a cross-validated 503 classification accuracy of 0.93. While the best spectral domain feature was the β band 504 PSD, with an average accuracy of 0.80. Overall, temporal domain features (average 505 accuracy: 0.78) outperformed spectral domain features (average accuracy: 0.71). 506 Notably, combining all the LFP features yielded superior performance compared to

507 individual features. Consistently, by investigating the logistic regression coefficients 508 of the neural biomarker model (Figure 10B), we found that the features with better 509 classification accuracy also had larger coefficients in the neural biomarker model, 510 again showing the importance of β band PSD and Hurst exponent.

We then examined the variations of β band PSD and Hurst exponent at the high, 511 512 transition and low symptom states. In terms of the spectral domain, the overall LFP PSD showed obvious changes during the three symptom states (Figure 10C), with the 513 β band PSD showing a significant and consistent decrease when changing from high 514 state, to transition state, and finally to low state (Figure 10D). By contrast, no 515 516 significant change was found for the θ band PSD and less consistent changes was found for the δ band and α band PSD (Figure 10D). In terms of the temporal domain, 517 the Hurst exponent showed an increase when changing from high state, to transition 518 519 state, and finally to low state (Figure 10E and 10F) while other representative 520 temporal domain features showed less obvious changes (Figure 10F). Together, these 521 results demonstrated the important contribution of the β band spectral feature and the Hurst exponent temporal feature to the identification of neural biomarker and the 522 523 tracking of depression symptom state.



Figure 10. Importance of the β band spectral feature and the Hurst exponent temporal feature to the identification of neural biomarker and the tracking of the depression symptom state. (A) Classification accuracy of individual features and all LFP features by separately training LR models. The individual spectral domain (SD) features are in green. and their indices are ordered based on classification accuracy. The individual temporal domain (TD) features are in blue, and their indices are ordered by classification accuracy. The combination of all LFP features is in brown. The best individual feature was indicated by a yellow star for each domain. (B) The absolute coefficients of each feature in the LR model trained with all LFP features. The feature indices are the same as in (A). (C) Changes in the average LFP spectrum from the high symptom state (High) to the transition symptom state (Trans), and finally to the low symptom state (Low). (D) Changes in each of the four frequency bands with individual feature classification accuracy (Acc) indicated below. Twosided Wilcoxon rank-sum test was used for significance test. Asterisks indicate the significance levels *p<0.05, **p<0.01, ***p<0.001, and ns indicates no significance. (E) Changes in the temporal domain feature Hurst exponent from High to Trans to Low state. (F) Same as (D) but for four example temporal domain features.

524

525

3.8 The identified neural biomarker and its contributing features indicated changes in LHb excitatory/inhibition (E/I) balance

526 We then interpreted the identified neural biomarker by relating it to the E/I balance of LHb activity. We used the LHb LFP spectrum's 1/f slope as a possible indicator of 527 LHb E/I balance, where a larger absolute 1/f slope indicates more inhibition (see 528 Section 2.9). We found that after DBS treatment, the LHb activity changed to a more 529 530 inhibitory state (Figure 11A). More specifically, the LHb E/I balance indicator 531 increased when high symptom state changed to low symptom state (Figure 11B) and 532 showed a trend of increase during the entire DBS treatment process (Figure 11C). consistently indicating an increase of inhibition. Moreover, we found a significant 533 534 positive correlation between the identified neutral biomarker and the LHb E/I balance indicator (Figure 11D, Spearman's $\rho = 0.78$, $P = 2.7 \times 10^{-6}$). Further, the most 535 536 contributing Hurst exponent temporal feature and β band spectral feature both significantly correlated with the LHb E/I balance indicator (Figure 11D, Hurst 537 exponent: Spearman's $\rho = -0.80$, $P = 1.9 \times 10^{-28}$; β band PSD: Spearman's 538 $\rho = 0.20, P = 2.8 \times 10^{-2}$). These results suggest that LHb E/I balance changed 539 540 towards more inhibition following DBS treatment and our identified neural biomarker 541 and its most contributing features significantly tracked such a change in LHb E/I 542 balance.



Figure 11. Changes of E/I balance during LHb DBS treatment and its' correlations with the identified neural biomarker and the most contributing features. (A) Overview of the LHb E/I balance change after DBS treatment. (B) LHb LFP spectrum's 1/f slope of two example days in high symptom state and low symptom state, respectively. The LFP spectrum's 1/f slope is taken as the E/I balance indicator. (C) Temporal trace of baseline-normalized daily LHb E/I balance indicator. (D) Correlation between the E/I balance indicator and the identified neural biomarker (left), between the E/I balance indicator and the Hurst exponent (middle), and the E/I balance indicator and the β band PSD (right).

544 **3.9** The DBS treatment involved a critical LHb-DRN circuit that

545

possibly regulates depression via E/I balancing

After finding a connection between the neural biomarker and LHb E/I balance, we finally investigated the underlying neural circuits of LHb E/I balance. We used diffusion tensor imaging to obtain white matter fibers related to LHb and found that strong white matter fiber connections exist between LHb and the dorsal raphe nucleus (DRN) in our patient (Figure 12A).

551 The LHb-DRN circuit is a critical pathway involved in central serotonergic 552 regulation. This circuit plays a role in regulating cognition and reward, both of which 553 are essential symptom dimensions associated with depression. The involvement of 554 the LHb-DRN circuit suggests a possible mechanism of DBS treatment in our patient (also see Section 4.3). Specifically, prior studies have shown that in depressed 555 patients, the LHb activity is overly excited (unbalanced E/I towards excitation), thus 556 557 exerting substantial inhibition on the DRN via the inhibitory connections between LHb and DRN, consequently leading to reduced serotonin output from the DRN. 558 559 Such a reduction in serotonin further inhibits the hippocampus and medial prefrontal 560 cortex activity, possibly asserting influence on the cognitive dimension of depression; 561 it also inhibits the nucleus accumbens activity, possibly asserting influence on the reward dimension of depression (Figure 12B). Our results suggest that LHb DBS 562 563 treatment moved the LHb activity to a more inhibitory state, possibly restoring the 564 LHb E/I balance towards a normal state and improving the depression symptoms 565 (especially cognition functions and emotion blunting, see Section 3.1) via the critical 566 regulation pathway involving LHb and DRN.



Figure 12. Diffusion tensor imaging of the white matter tracks related to LHb and a possible regulation pathway for depression. (A) Diffusion tensor imaging of the white matter tracks related to LHb. The DBS target (left LHb) and the connected brain area (DRN) were circled in red. Note that while the right LHb was not stimulated, its related white matter fibers are also shown. (B) LHb-DRN circuit and its possible role in regulating the cognition and reward dimensions of depression symptom. Hip: hippocampus; mPFC: medial prefrontal cortex; NAc: nucleus accumbens.

567 4. Discussion

4.1 Improvement of depression symptoms, emotional blunting, and cognitive function during DBS treatment

570 The clinical evaluation results show that our patient not only achieved improvements 571 of HAMD, MADRS, and HAMA ratings that are typically used as clinical gold 572 standard in prior DBS studies [11,13,17], but also achieved notable improvements of 573 emotional blunting and cognition functioning. Almost three-quarters of patients in the 574 acute phase of depression and one-quarter of those in remission reported severe 575 emotional blunting. Approximately 56% of patients considered their emotional 576 blunting to be caused by their depression, while 45% believed that their 577 antidepressant medication was negatively affecting their emotions [63]. Emotional blunting has a substantial negative impact on patients' daily functioning, well-being, 578 579 and quality of life in both the acute and remission phases of depression [64]. On the

580 other hand, cognitive deficits may be inherent to TRD and occur independently of 581 affective symptomatology [65]. Objective cognitive assessment for the clinical 582 evaluation for patients with TRD is important [66]. Thus, in our TRD patient, we 583 specifically addressed the evaluation of both emotional blunting and cognitive 584 functioning and showed improvements along both aspects.

585 However, our results regarding emotional blunting and cognitive functioning should be interpreted cautiously because of the lack of controlled data. Due to limited 586 data about cognition in this case, we did not identify a neural biomarker to classify 587 these cognitive states. The cognitive impact of DBS has usually been previously 588 589 evaluated for epilepsy, movement disorder, and obsessive-compulsive disorder patients but rarely in controlled studies on TRD. Our study found no cognitive decline 590 591 and suggests positive effects of DBS on cognitive functioning in TRD consistent with 592 a previous report [67].

593 4.2 A data-driven LHb neural biomarker for tracking slow and

594

fast depression symptom variations during DBS treatment

595 A mechanism-driven neural biomarker for depression is currently lacking mainly 596 because the neural circuitry underlying depression has not been clearly delineated [68]. Therefore, current neural biomarkers of depression symptoms for tracking DBS 597 598 effects have largely used data-driven machine learning methods to map LFP features 599 to depression symptom ratings [17,32,33]. The usefulness of data-driven neural 600 biomarkers critically depends on the type of data used to identify the neural biomarker. 601 For example, a recent work [32] focused on a cingulate neural biomarker that was trained with and accordingly predicted longer-term (on the time scale of weeks) 602

603 clinical ratings. On the other hand, another recent work [17] only trained and tested a 604 neural biomarker with shorter-term (on the time scale of minutes) self-reports. Our 605 work is unique in that, while we identified our LHb neural biomarker based on weekly clinical ratings, we demonstrated that the neural biomarker predicted not only weekly 606 607 clinical ratings (data not used in identification) but also daily self-reports (data again 608 not used in identification). The results suggest that our LHb neural biomarker could 609 track the temporal dynamics of both slow and fast depression symptom variations, 610 which was useful for developing new aDBS strategies that are robust across different time scales. It is worth noting that our LHb neural biomarker specifically tracked the 611 612 temporal dynamics of weekly and daily depression symptom scores but not the 613 anxiety symptom scores. It suggests that despite the overlapping of depression-related and anxiety-related brain networks [69], LHb neural activity is mainly related to 614 depression, which is supported by prior animal studies [21-23]. 615

616 Both population-level and personalized neural biomarkers of depression 617 symptoms have been identified for tracking DBS effects. Population-level neural 618 biomarkers are derived from data collected from several patients and have the benefits 619 of being directly applicable to a new patient and robust interpretability of the neural 620 biomarker's biophysical mechanism across patients [32]. By contrast, personalized neural biomarkers are derived from data collected from an individual patient, which 621 622 is more powerful in capturing the unique characteristics of depression symptoms in 623 each patient, especially given the large inter-individual variability in depression-624 related brain networks [70]. With the emerging capability of recording more data within a single patient using mobile devices, personalized neural biomarker models 625 can be more accurate in tracking the temporal dynamics of depression symptom 626

627 variations. With such trends, a personalized neural biomarker has been identified and used for realizing aDBS targeting VC/VS [17]. Our study identified a personalized 628 629 neural biomarker that achieved accurate classification and tracking of depression symptom variations during the DBS treatment targeting LHb, confirming the 630 631 usefulness of personalization. Nevertheless, population-level and personalized neural 632 biomarkers can complement each other. For example, one can leverage a large amount 633 of population data to train an interpretable population-level neural biomarker model, followed by fine-tuning with personalized data to further improve its accuracy, which 634 is an important future research direction. 635

636 A critical issue in identifying data-driven neural biomarker, especially personalized neural biomarker, is the collection of sufficient amounts of data. A recent 637 638 population-level study collected LFP and clinical rating data from 5 individuals on a 639 weekly basis over a span of 24 weeks [32], resulting in a total data sample size of 120, 640 which was deemed sufficient for obtaining a neural biomarker at the population level. 641 Several personalized studies collected LFP or iEEG and self-report data over several 642 days, with a data sample size of around 30 for each individual [17,33]. By contrast, 643 our study involved daily data collection over a much longer period of 41 weeks. Even 644 after removing noisy data epochs, our data-driven neural biomarker analyses were 645 based on a substantial data sample size of 122 days, which significantly exceeded the 646 data sample size of one individual in the aforementioned studies. Our robustness 647 analyses confirmed the sufficiency of our data sample size, showing that in our patient, 648 the neural biomarker performance maintained stable even after reducing the data sample size to around 70 but had significant variations after reducing the data sample 649 size below 40. This result indicates the importance of collecting sufficient data for 650

identifying personalized neural biomarkers. The ongoing advancements in data recording devices offer exciting prospects for recording more data samples within an individual, thus facilitating the future development of personalized neural biomarkers.

biomarker and its contributing features in terms of LHb E/I

654

4 4.3 Neurobiological interpretation of the identified neural

655

656

balance

657 Previous studies have exclusively used LFP spectral domain features to identify 658 neural biomarkers for depression [17,32,33]. By contrast, we found that both the LFP 659 temporal domain and spectral domain features contributed to our neural biomarker and that the temporal domain features contributed relatively more than the spectral 660 661 domain features. The main contributing temporal domain feature was the Hurst exponent. The Hurst exponent mainly indicates the stochasticity and predictability of 662 663 a time-series [71]. We found that during the high and transition symptom states, the 664 LHb LFP Hurst exponent values were mostly below 0.5, which indicated more 665 stochastic and random-walk-like neural dynamics [72]. By contrast, during the low 666 symptom state towards the end of DBS treatment, the LHb LFP Hurst exponent values 667 were approaching and even surpassing 0.5, which indicated more predictable and 668 stable neural dynamics [73]. Stochastic vs. predictable neural dynamics have been 669 reported to relate with E/I balance of neural firing [74]. Related to this explanation, 670 Hurst exponent has been widely used to examine E/I balance of the neural circuits in other neuropsychiatric disorders such as autism [75,76]. Our results suggest that a 671 672 DBS-induced increase in LHb inhibition led to an increase in the Hurst exponent, 673 moving LHb activity to a more E/I balanced state.

674 The main contributing spectral domain feature was the β band PSD. The LHb β 675 band oscillation was also found to correlate with depression symptoms before DBS 676 treatment in a previous study [28]. The β band oscillation might reflect the abnormal E/I balance of LHb neural ensembles underlying depression because it can depend on 677 the firing patterns of a network of inhibitory interneurons gated by their mutually 678 induced GABA_A action [77]. Moreover, LHb β band oscillation might be related to 679 680 the abnormal burst spiking phenomena of LHb neurons found in rodents exhibiting 681 depression-like behaviors [21–23]. These findings highlight the significance of the β band oscillations in LHb as related to depression. 682

683 Existing neuroscience findings provide evidence that LHb E/I balance 684 influences the dopaminergic and serotoninergic projections from LHb and directly 685 affects two neural pathways: the LHb-VTA (ventral tegmental area) pathway mainly regulates the dopaminergic activity, while the LHb-DRN pathway primarily regulates 686 the serotoninergic activity [34]. Our white fiber tracking results predominantly 687 reflected the influence of DBS on the LHb-DRN pathway. The DBS might have 688 689 inhibited overly-excited LHb activity, activating overly-inhibited DRN activity, and 690 restoring downstream neural activity related to cognition and reward circuits related 691 to depression, which finally led to the multi-faceted improvement of depression symptoms, emotional blunting, and cognitive functioning of our patient. However, 692 693 due to the complexity of LHb-related circuits, the exact neural activity changes of the 694 LHb-related circuit in DBS treatment of depression requires further investigation by 695 collecting multimodal neural data from more brain regions.

It is worth noting that due to the limitation of DBS electrode, we only used a simple LFP 1/f slope as an indirect indicator for LHb E/I balance. The E/I balance is

698 directly related to the spiking activity of excitatory neurons and inhibitory neurons, and further related to the neuronal homeostasis and the formation of neural 699 700 oscillations [78,79]. The underlying excitatory and inhibitory neuron synaptic 701 currents mix together to give rise to the 1/f-like nature of the LFP PSD [34]. Previous 702 study found that alterations of E/I balance within neural circuits can indeed be inferred 703 from changes in the LFP 1/f slope [80]. Nevertheless, the LFP signal represents the 704 collective activity of multiple neurons and only provides an indirect measure of E/I 705 balance. Future work can use more advanced micro-macro electrodes [81] to record 706 LHb spiking activity to more directly quantify LHb E/I balance.

707 4.4 DBS frequency deferentially modulates the depression

708

symptom and neural biomarker

709 Prior studies have shown that DBS frequency can significantly influence the treatment 710 efficacy for TRD, e.g., high-frequency DBS has generally yielded better treatment 711 outcomes than low-frequency DBS [24,82,83]. Consistently, we discovered that a very low DBS frequency of 1 Hz was not effective in alleviating the depression 712 symptoms in our patient, but higher frequencies of 20 Hz and 130 Hz were more 713 714 effective. Beyond the depression symptom ratings, we additionally found that the 715 neural biomarker was also consistently modulated by the different DBS frequencies. 716 DBS frequency might influence the release of neurotransmitters in depression-717 targeted pathways [84], thus modulating the neural biomarker and the depression 718 symptoms. However, similar to other DBS targets, the optimal DBS frequency at LHb 719 is still also an open question that requires further research.

720 5. Limitations

721 Our study has several limitations. First, while our study had a sufficient within-patient data sample size, the patient sample size was limited (n-of-1); further studies with 722 723 more patients are needed to confirm our findings on LHb neural biomarkers. Second, 724 despite its powerful classification and tracking performance, our neural biomarker was identified using only one channel of LFP signals due to the limitation of device 725 hardware configuration. Incorporating multi-channel LFP signals in future studies 726 727 would allow for finding neural biomarkers with even better performance and a more comprehensive understanding of the neural mechanism underlying neural biomarker 728 identification. Third, due to the high-frequency recording noise of our DBS device, 729 730 we filtered the LFP signal below 30 Hz to ensure noise rejection. Future work with 731 better recording capability should investigate how higher-frequency LFP temporal 732 and spectral domain features contribute to the identification of neural biomarkers. 733 Finally, to remove the confounding factor of stimulation artifact, when we recorded 734 LFP, we completely turned off stimulation. While this approach ensured stimulation-735 artifact-free LFP signals, it is important to consider using LFP signals during 736 stimulation to identify better responsive neural biomarkers in the future, but this 737 requires high-performance stimulation artifact removal, which remains challenging 738 [85].

739 6. Conclusion

One patient with TRD reached remission after 41 weeks of LHb DBS treatment. Witha unique longitudinal data collection of concurrent daily and weekly depression

742 symptom scores and LHb LFP signals during the entire treatment process, we used 743 machine learning to identify an LHb neural biomarker of depression symptoms, with 744 the most contributing spectral feature being LFP β band power and temporal feature being Hurst exponent. We demonstrated that our LHb neural biomarker accurately 745 classified high and low depression symptom severity states, simultaneously tracked 746 the temporal dynamics of weekly (slow) and daily (fast) depression symptom 747 748 variations during the DBS treatment process, and reflected the depression symptom changes in response to DBS frequency alterations. We also interpreted the neural 749 biomarker as indicating changes in LHb excitatory/inhibition balance during DBS 750 treatment. Our methods and results hold promise in identifying clinically-viable 751 752 neural biomarkers to facilitate future adaptive DBS developments for treating TRD.

753 **Data availability**

The data supporting this study's findings are available from the corresponding authorupon reasonable request.

756 Funding

This work was supported in part by the National Natural Science Foundation of China under Grants 62336007, 62306269 and 62476239, in part by the Zhejiang Provincial Natural Science Foundation of China under Grant LD24H090001, in part by the Starry Night Science Fund of Zhejiang University Shanghai Institute for Advanced Study under Grant SN-ZJU-SIAS-002, and in part by the Fundamental Research Funds for the Central Universities under Grant 226-2024-00127.

763 Author Contributions

Shi Liu: Methodology, Software, Formal analysis, Writing - Original Draft,
Visualization. Yu Oi: Investigation, Resources. Shaohua Hu: Conceptualization,

766 Resources. Ning Wei: Resources, Data Curation, Writing - Original Draft. Jianmin

- 767 Zhang: Conceptualization, Resources, Junming Zhu: Conceptualization, Resources,
- 768 Hemmings Wu: Conceptualization, Investigation. Hailan Hu: Conceptualization.
- 769 Yuxiao Yang: Conceptualization, Supervision, Methodology, Writing Review &
- 770 Editing, Funding acquisition. Yueming Wang: Conceptualization, Supervision,
- 771 Project administration, Funding acquisition, Writing Review & Editing. All authors
- revised and approved the final version of the manuscript.

773 **Conflict of Interest**

There are no financial conflicts of interest to disclose.

775 **References**

- 776 [1] Organization WH, others. Depression and other common mental disorders:777 global health estimates. World Health Organization; 2017.
- 778 [2] Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major
 779 depressive disorder. Nat Rev Dis Primers 2016;2:16065.
 780 https://doi.org/10.1038/nrdp.2016.65.
- [3] Krauss JK, Lipsman N, Aziz T, Boutet A, Brown P, Chang JW, et al.
 Technology of deep brain stimulation: current status and future directions. Nat Rev Neurol 2021;17:75–87. https://doi.org/10.1038/s41582-020-00426-z.
- [4] Dandekar MP, Fenoy AJ, Carvalho AF, Soares JC, Quevedo J. Deep brain stimulation for treatment-resistant depression: an integrative review of preclinical and clinical findings and translational implications. Mol Psychiatry 2018;23:1094–112. https://doi.org/10.1038/mp.2018.2.

- Figee M, Riva-Posse P, Choi KS, Bederson L, Mayberg HS, Kopell BH. Deep
 Brain Stimulation for Depression. Neurotherapeutics 2022;19:1229–45.
 https://doi.org/10.1007/s13311-022-01270-3.
- Johnson KA, Okun MS, Scangos KW, Mayberg HS, de Hemptinne C. Deep
 brain stimulation for refractory major depressive disorder: a comprehensive
 review. Mol Psychiatry 2024:1–13. https://doi.org/10.1038/s41380-02302394-4.
- [7] Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C,
 et al. Deep Brain Stimulation for Treatment-Resistant Depression. Neuron
 2005;45:651–60. https://doi.org/10.1016/j.neuron.2005.02.014.
- [8] Malone DA, Dougherty DD, Rezai AR, Carpenter LL, Friehs GM, Eskandar
 EN, et al. Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for
 Treatment-Resistant Depression. Biol Psychiatry 2009;65:267–75.
 https://doi.org/10.1016/j.biopsych.2008.08.029.
- Schlaepfer TE, Bewernick BH, Kayser S, Mädler B, Coenen VA. Rapid Effects
 of Deep Brain Stimulation for Treatment-Resistant Major Depression. Biol
 Psychiatry 2013;73:1204–12. https://doi.org/10.1016/j.biopsych.2013.01.034.
- [10] Neumann W-J, Huebl J, Brücke C, Gabriëls L, Bajbouj M, Merkl A, et al.
 Different patterns of local field potentials from limbic DBS targets in patients
 with major depressive and obsessive compulsive disorder. Mol Psychiatry
 2014;19:1186–92. https://doi.org/10.1038/mp.2014.2.
- Bergfeld IO, Mantione M, Hoogendoorn MLC, Ruhe HG, Notten P, van
 Laarhoven J, et al. Deep Brain Stimulation of the Ventral Anterior Limb of the
 Internal Capsule for Treatment-Resistant Depression A Randomized Clinical
 Trial. Jama Psychiatry 2016;73:456–64.
 https://doi.org/10.1001/jamapsychiatry.2016.0152.
- [12] Dougherty DD, Rezai AR, Carpenter LL, Howland RH, Bhati MT, O'Reardon
 JP, et al. A Randomized Sham-Controlled Trial of Deep Brain Stimulation of
 the Ventral Capsule/Ventral Striatum for Chronic Treatment-Resistant
 Depression. Biol Psychiatry 2015;78:240–8.
 https://doi.org/10.1016/j.biopsych.2014.11.023.
- [13] Holtzheimer PE, Husain MM, Lisanby SH, Taylor SF, Whitworth LA,
 McClintock S, et al. Subcallosal cingulate deep brain stimulation for treatmentresistant depression: a multisite, randomised, sham-controlled trial. Lancet
 Psychiatry 2017;4:839–49. https://doi.org/10.1016/S2215-0366(17)30371-1.
- [14] Coenen VA, Bewernick BH, Kayser S, Kilian H, Boström J, Greschus S, et al.
 Superolateral medial forebrain bundle deep brain stimulation in major
 depression: a gateway trial. Neuropsychopharmacology 2019;44:1224–32.
 https://doi.org/10.1038/s41386-019-0369-9.
- Raymaekers S, Luyten L, Bervoets C, Gabriëls L, Nuttin B. Deep brain
 stimulation for treatment-resistant major depressive disorder: a comparison of

- two targets and long-term follow-up. Transl Psychiatry 2017;7:e1251–e1251.
 https://doi.org/10.1038/tp.2017.66.
- [16] Guidetti M, Marceglia S, Loh A, Harmsen IE, Meoni S, Foffani G, et al.
 Clinical perspectives of adaptive deep brain stimulation. Brain Stimul
 2021;14:1238–47. https://doi.org/10.1016/j.brs.2021.07.063.
- Scangos KW, Khambhati AN, Daly PM, Makhoul GS, Sugrue LP, Zamanian
 H, et al. Closed-loop neuromodulation in an individual with treatment-resistant
 depression. Nat Med 2021;27:1696–700. https://doi.org/10.1038/s41591-02101480-w.
- Hu H, Cui Y, Yang Y. Circuits and functions of the lateral habenula in health
 and in disease. Nat Rev Neurosci 2020;21:277–95.
 https://doi.org/10.1038/s41583-020-0292-4.
- [19] Roman E, Weininger J, Lim B, Roman M, Barry D, Tierney P, et al. Untangling
 the dorsal diencephalic conduction system: a review of structure and function
 of the stria medullaris, habenula and fasciculus retroflexus. Brain Struct Funct
 2020;225:1437–58. https://doi.org/10.1007/s00429-020-02069-8.
- B45 [20] Dai D, Li W, Chen A, Gao X-F, Xiong L. Lateral Habenula and Its Potential
 B46 Roles in Pain and Related Behaviors. ACS Chem Neurosci 2022;13:1108–18.
 B47 https://doi.org/10.1021/acschemneuro.2c00067.
- Cui Y, Yang Y, Dong Y, Hu H. Decoding Depression: Insights from Glial and Ketamine Regulation of Neuronal Burst Firing in Lateral Habenula. Cold
 Spring Harb Symp Quant Biol 2018;83:141–50. https://doi.org/10.1101/sqb.2018.83.036871.
- [22] Cui Y, Yang Y, Ni Z, Dong Y, Cai G, Foncelle A, et al. Astroglial Kir4.1 in the
 lateral habenula drives neuronal bursts in depression. Nature 2018;554:323–7.
 https://doi.org/10.1038/nature25752.
- Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, et al. Ketamine blocks bursting in
 the lateral habenula to rapidly relieve depression. Nature 2018;554:317–22.
 https://doi.org/10.1038/nature25509.
- Sartorius A, Kiening KL, Kirsch P, Gall CC von, Haberkorn U, Unterberg AW,
 et al. Remission of Major Depression Under Deep Brain Stimulation of the
 Lateral Habenula in a Therapy-Refractory Patient. Biol Psychiatry 2010;67:e9–
 11. https://doi.org/10.1016/j.biopsych.2009.08.027.
- [25] Wang Z, Cai X, Qiu R, Yao C, Tian Y, Gong C, et al. Case Report: Lateral
 Habenula Deep Brain Stimulation for Treatment-Resistant Depression. Front
 Psychiatry 2021;11. https://doi.org/10.3389/fpsyt.2020.616501.
- Kiening K, Sartorius A. A new translational target for deep brain stimulation to
 treat depression. EMBO Molecular Medicine 2013;5:1151–3.
 https://doi.org/10.1002/emmm.201302947.
- [27] Zhang C, Kim S-G, Li D, Zhang Y, Li Y, Husch A, et al. Habenula deep brain
 stimulation for refractory bipolar disorder. Brain Stimulation 2019;12:1298–
 300. https://doi.org/10.1016/j.brs.2019.05.010.

- [28] Zhang C, Zhang Y, Luo H, Xu X, Yuan T, Li D, et al. Bilateral Habenula deep
 brain stimulation for treatment-resistant depression: clinical findings and
 electrophysiological features. Transl Psychiatry 2022;12:52.
 https://doi.org/10.1038/s41398-022-01818-z.
- [29] Wang Z, Jiang C, Guan L, Zhao L, Fan T, Wang J, et al. Deep brain stimulation
 of habenula reduces depressive symptoms and modulates brain activities in
 treatment-resistant depression. Nat Mental Health 2024.
 https://doi.org/10.1038/s44220-024-00286-2.
- [30] Vissani M, Isaias IU, Mazzoni A. Deep brain stimulation: a review of the open neural engineering challenges. J Neural Eng 2020;17:051002.
 https://doi.org/10.1088/1741-2552/abb581.
- [31] Priori A, Maiorana N, Dini M, Guidetti M, Marceglia S, Ferrucci R. Chapter
 Six Adaptive deep brain stimulation (aDBS). In: Moro E, Polosan M, Hamani
 C, editors. Int Rev Neurobiol, vol. 159, Academic Press; 2021, p. 111–27.
 https://doi.org/10.1016/bs.irn.2021.06.006.
- [32] Alagapan S, Choi KS, Heisig S, Riva-Posse P, Crowell A, Tiruvadi V, et al.
 Cingulate dynamics track depression recovery with deep brain stimulation.
 Nature 2023:1–9. https://doi.org/10.1038/s41586-023-06541-3.
- Frank AC, Scangos KW, Larson PS, Norbu T, Lee AT, Lee AM. Identification
 of a personalized intracranial biomarker of depression and response to DBS
 therapy. Brain Stimul 2021;14:1002–4.
 https://doi.org/10.1016/j.brs.2021.06.009.
- [34] Sonkusare S, Ding Q, Zhang Y, Wang L, Gong H, Mandali A, et al. Power signatures of habenular neuronal signals in patients with bipolar or unipolar depressive disorders correlate with their disease severity. Transl Psychiatry 2022;12:1–9. https://doi.org/10.1038/s41398-022-01830-3.
- [35] Cobb BS, Coryell WH, Cavanaugh J, Keller M, Solomon DA, Endicott J, et al.
 Seasonal variation of depressive symptoms in unipolar major depressive
 disorder. Compr Psychiatry 2014;55:1891–9.
 https://doi.org/10.1016/j.comppsych.2014.07.021.
- 901 [36] Panaite V, Rottenberg J, Bylsma LM. Daily Affective Dynamics Predict
 902 Depression Symptom Trajectories Among Adults with Major and Minor
 903 Depression. Affect Sci 2020;1:186–98. https://doi.org/10.1007/s42761-020904 00014-w.
- Kennedy SH, Giacobbe P, Rizvi SJ, Placenza FM, Nishikawa Y, Mayberg HS, 905 [37] et al. Deep Brain Stimulation for Treatment-Resistant Depression: Follow-Up 906 907 After 3 to 6 Years. Am J Psychiatry 2011;168:502-10. 908 https://doi.org/10.1176/appi.aip.2010.10081187.
- 38] Bewernick BH, Kayser S, Sturm V, Schlaepfer TE. Long-Term Effects of Nucleus Accumbens Deep Brain Stimulation in Treatment-Resistant Depression: Evidence for Sustained Efficacy. Neuropsychopharmacology 2012;37:1975–85. https://doi.org/10.1038/npp.2012.44.

- [39] Crowell AL, Riva-Posse P, Holtzheimer PE, Garlow SJ, Kelley ME, Gross RE,
 et al. Long-Term Outcomes of Subcallosal Cingulate Deep Brain Stimulation
 for Treatment-Resistant Depression. Am J Psychiatry 2019;176:949–56.
 https://doi.org/10.1176/appi.ajp.2019.18121427.
- Peeters F, Berkhof J, Delespaul P, Rottenberg J, Nicolson NA. Diurnal mood
 variation in major depressive disorder. Emotion 2006;6:383–91.
 https://doi.org/10.1037/1528-3542.6.3.383.
- 920[41]Wirz-Justice A. Diurnal variation of depressive symptoms. Dialogues Clin921Neurosci2008;10:337–43.
- 922 https://doi.org/10.31887/DCNS.2008.10.3/awjustice.
- [42] Scangos KW, Makhoul GS, Sugrue LP, Chang EF, Krystal AD. State-dependent responses to intracranial brain stimulation in a patient with depression. Nat Med 2021;27:229–31. https://doi.org/10.1038/s41591-020-01175-8.
- [43] Bewernick BH, Kayser S, Gippert SM, Coenen VA, Schlaepfer TE. Acute
 antidepressant effects of deep brain stimulation Review and data from
 slMFB-stimulation. Pers Med Psychiatry 2017;3:1–7.
 https://doi.org/10.1016/j.pmip.2017.01.002.
- [44] Xiao J, Provenza NR, Asfouri J, Myers J, Mathura RK, Metzger B, et al.
 Decoding Depression Severity From Intracranial Neural Activity. Biol
 Psychiatry 2023;94:445–53. https://doi.org/10.1016/j.biopsych.2023.01.020.
- [45] Sani OG, Yang Y, Lee MB, Dawes HE, Chang EF, Shanechi MM. Mood
 variations decoded from multi-site intracranial human brain activity. Nat
 Biotechnol 2018;36:954–61. https://doi.org/10.1038/nbt.4200.
- [46] Kirkby LA, Luongo FJ, Lee MB, Nahum M, Vleet TMV, Rao VR, et al. An
 Amygdala-Hippocampus Subnetwork that Encodes Variation in Human Mood.
 Cell 2018;175:1688-1700.e14. https://doi.org/10.1016/j.cell.2018.10.005.
- [47] Ashkan K, Rogers P, Bergman H, Ughratdar I. Insights into the mechanisms of
 deep brain stimulation. Nat Rev Neurol 2017;13:548–54.
 https://doi.org/10.1038/nrneurol.2017.105.
- [48] Ramasubbu R, Lang S, Kiss ZHT. Dosing of Electrical Parameters in Deep
 Brain Stimulation (DBS) for Intractable Depression: A Review of Clinical
 Studies. Front Psychiatry 2018;9. https://doi.org/10.3389/fpsyt.2018.00302.
- 945 [49] Okun M, Lampl I. Balance of excitation and inhibition. Scholarpedia
 946 2009;4:7467. https://doi.org/10.4249/scholarpedia.7467.
- Hu H, Cui Y, Yang Y. Circuits and functions of the lateral habenula in health
 and in disease. Nat Rev Neurosci 2020;21:277–95.
 https://doi.org/10.1038/s41583-020-0292-4.
- Balcita-Pedicino JJ, Omelchenko N, Bell R, Sesack SR. The inhibitory 950 [51] influence of the lateral habenula on midbrain dopamine cells: Ultrastructural 951 evidence for indirect mediation via the rostromedial mesopontine tegmental 952 953 nucleus. of Comparative Neurology 2011;519:1143-64. Journal 954 https://doi.org/10.1002/cne.22561.

- [52] Sun Y, Cao J, Xu C, Liu X, Wang Z, Zhao H. Rostromedial tegmental nucleussubstantia nigra pars compacta circuit mediates aversive and despair behavior
 in mice. Experimental Neurology 2020;333:113433.
 https://doi.org/10.1016/j.expneurol.2020.113433.
- [53] Zhu Z, Hubbard E, Guo X, Barbosa DAN, Popal AM, Cai C, et al. A
 connectomic analysis of deep brain stimulation for treatment-resistant
 depression. Brain Stimul 2021;14:1226–33.
 https://doi.org/10.1016/j.brs.2021.08.010.
- 963 [54] Yeung AWK, Wong NSM. The Historical Roots of Visual Analog Scale in
 964 Psychology as Revealed by Reference Publication Year Spectroscopy. Front
 965 Hum Neurosci 2019;13. https://doi.org/10.3389/fnhum.2019.00086.
- Schiratti J-B, Le Douget J-E, Le van Quyen M, Essid S, Gramfort A. An
 ensemble learning approach to detect epileptic seizures from long intracranial
 EEG recordings. ICASSP 2018 2018 IEEE International Conference on
 Acoustics, Speech and Signal Processing (ICASSP, Calgary, Canada: IEEE;
 2018. https://doi.org/10.1109/ICASSP.2018.8461489.
- [56] Banville H, Wood SUN, Aimone C, Engemann D-A, Gramfort A. Robust
 learning from corrupted EEG with dynamic spatial filtering. NeuroImage
 2022;251:118994. https://doi.org/10.1016/j.neuroimage.2022.118994.
- 974 [57] Engemann DA, Mellot A, Höchenberger R, Banville H, Sabbagh D, Gemein L,
 975 et al. A reusable benchmark of brain-age prediction from M/EEG resting-state
 976 signals. NeuroImage 2022;262:119521.
 977 https://doi.org/10.1016/j.neuroimage.2022.119521.
- [58] Giorgino T. Computing and Visualizing Dynamic Time Warping Alignments in
 R: The dtw Package. J Stat Softw 2009;31:1–24.
 https://doi.org/10.18637/jss.v031.i07.
- [59] Sakoe H, Chiba S. Dynamic programming algorithm optimization for spoken
 word recognition. IEEE Trans Acoust Speech Signal Process 1978;26:43–9.
 https://doi.org/10.1109/TASSP.1978.1163055.
- Veerakumar A, Tiruvadi V, Howell B, Waters AC, Crowell AL, Voytek B, et al.
 Field potential 1/f activity in the subcallosal cingulate region as a candidate
 signal for monitoring deep brain stimulation for treatment-resistant depression.
 J Neurophysiol 2019;122:1023–35. https://doi.org/10.1152/jn.00875.2018.
- Arbuthnott K, Frank J. Trail Making Test, Part B as a Measure of Executive
 Control: Validation Using a Set-Switching Paradigm. J Clin Exp Neuropsychol
 2000;22:518–28. https://doi.org/10.1076/1380-3395(200008)22:4;1-0;FT518.
- [62] Salthouse TA. What Do Adult Age Differences in the Digit Symbol Substitution
 Test Reflect? J Gerontol 1992;47:P121-8.
 https://doi.org/10.1093/geronj/47.3.P121.
- [63] Christensen MC, Ren H, Fagiolini A. Emotional blunting in patients with
 depression. Part I: clinical characteristics. Ann Gen Psychiatry 2022;21:10.
 https://doi.org/10.1186/s12991-022-00387-1.

- P97 [64] Christensen MC, Ren H, Fagiolini A. Emotional blunting in patients with
 depression. Part II: relationship with functioning, well-being, and quality of life.
 Ann Gen Psychiatry 2022;21:20. https://doi.org/10.1186/s12991-022-00392-4.
- Gonda X, Pompili M, Serafini G, Carvalho AF, Rihmer Z, Dome P. The role of
 cognitive dysfunction in the symptoms and remission from depression. Ann
 Gen Psychiatry 2015;14:27. https://doi.org/10.1186/s12991-015-0068-9.
- Bortolato B, Miskowiak KW, Köhler CA, Maes M, Fernandes BS, Berk M, et
 al. Cognitive remission: a novel objective for the treatment of major depression?
 BMC Med 2016;14:9. https://doi.org/10.1186/s12916-016-0560-3.
- Runia N, Mol GJJ, Hillenius T, Hassanzadeh Z, Denys D a. JP, Bergfeld IO.
 Effects of deep brain stimulation on cognitive functioning in treatment-resistant
 depression: a systematic review and meta-analysis. Mol Psychiatry
 2023;28:4585–93. https://doi.org/10.1038/s41380-023-02262-1.
- [68] Knowland D, Lim BK. Circuit-based frameworks of depressive behaviors: The
 role of reward circuitry and beyond. Pharmacol Biochem Behav 2018;174:42–
 52. https://doi.org/10.1016/j.pbb.2017.12.010.
- [69] Kalin NH. The Critical Relationship Between Anxiety and Depression. Am J
 Psychiatry 2020;177:365–7. https://doi.org/10.1176/appi.ajp.2020.20030305.
- [70] Sampogna G, Toni C, Catapano P, Rocca BD, Di Vincenzo M, Luciano M, et
 al. New trends in personalized treatment of depression. Curr Opin Psychiatry
 2024;37:3. https://doi.org/10.1097/YCO.000000000000903.
- [71] Carbone A, Castelli G, Stanley HE. Time-dependent Hurst exponent in
 financial time series. Physica A: Statistical Mechanics and Its Applications
 2004;344:267-71. https://doi.org/10.1016/j.physa.2004.06.130.
- [72] Kale M, Butar Butar F. Fractal analysis of time series and distribution
 properties of Hurst exponent. J Math Sci Math Educ 2011;5:8–19.
- Díaz M. HA, Córdova F. On the meaning of Hurst entropy applied to EEG data
 series. Procedia Computer Science 2022;199:1385–92.
 https://doi.org/10.1016/j.procs.2022.01.175.
- [74] Latham PE, Richmond BJ, Nelson PG, Nirenberg S. Intrinsic Dynamics in Neuronal Networks. I. Theory. Journal of Neurophysiology 2000;83:808–27. https://doi.org/10.1152/jn.2000.83.2.808.
- Pretzsch CM, Floris DL. Balancing excitation and inhibition in the autistic
 brain. eLife 2020;9:e60584. https://doi.org/10.7554/eLife.60584.
- Trakoshis S, Martínez-Cañada P, Rocchi F, Canella C, You W, Chakrabarti B, 031 [76] et al. Intrinsic excitation-inhibition imbalance affects medial prefrontal cortex 032 women. 033 differently in autistic men versus eLife 2020;9:e55684. 034 https://doi.org/10.7554/eLife.55684.
- Porjesz B, Almasy L, Edenberg HJ, Wang K, Chorlian DB, Foroud T, et al.
 Linkage disequilibrium between the beta frequency of the human EEG and a
 GABAA receptor gene locus. Proceedings of the National Academy of
 Sciences 2002;99:3729–33. https://doi.org/10.1073/pnas.052716399.

- [78] Turrigiano GG, Nelson SB. Homeostatic plasticity in the developing nervous
 system. Nat Rev Neurosci 2004;5:97–107. https://doi.org/10.1038/nrn1327.
- [79] Atallah BV, Scanziani M. Instantaneous Modulation of Gamma Oscillation
 Frequency by Balancing Excitation with Inhibition. Neuron 2009;62:566–77.
 https://doi.org/10.1016/j.neuron.2009.04.027.
- Gao R, Peterson EJ, Voytek B. Inferring synaptic excitation/inhibition balance
 from field potentials. NeuroImage 2017;158:70–8.
 https://doi.org/10.1016/j.neuroimage.2017.06.078.
- D47 [81] Daume J, Kamiński J, Schjetnan AGP, Salimpour Y, Khan U, Kyzar M, et al.
 D48 Control of working memory by phase–amplitude coupling of human
 D49 hippocampal neurons. Nature 2024;629:393–401.
 D50 https://doi.org/10.1038/s41586-024-07309-z.
- [82] Liu Y, Postupna N, Falkenberg J, Anderson ME. High frequency deep brain
 stimulation: What are the therapeutic mechanisms? Neurosci Biobehav Rev
 2008;32:343–51. https://doi.org/10.1016/j.neubiorev.2006.10.007.
- [83] Sani S, Busnello J, Kochanski R, Cohen Y, Gibbons RD. High-frequency measurement of depressive severity in a patient treated for severe treatmentresistant depression with deep-brain stimulation. Transl Psychiatry 2017;7:e1207–e1207. https://doi.org/10.1038/tp.2017.145.
- McIntyre CC, Anderson RW. Deep brain stimulation mechanisms: the control of network activity via neurochemistry modulation. J Neurochem 2016;139:338–45. https://doi.org/10.1111/jnc.13649.
- [85] Iturrate I, Pereira M, Millán J del R. Closed-loop electrical neurostimulation:
 Challenges and opportunities. Curr Opin Biomed Eng 2018;8:28–37.
 https://doi.org/10.1016/j.cobme.2018.09.007.

064